Catalent, Novo Holdings

Novo Holdings closes $16.5 billion buyout of contract manufacturer Catalent
Novo Holdings, the controlling shareholder of Novo Nordisk, on Wednesday sealed its $16.5 billion deal for Catalent, as the Danish drugmaker looks to boost supplies of its widely popular weight-loss drug Wegovy.
Novo Holdings says its acquisition of Catalent is complete.
Novo Nordisk plans to buy from the holding company three sites — Brussels; Anagni, Italy; and Bloomington — for $11.7 billion.
Catalent Acquired by Novo Holdings in $16.5 Billion Deal
The latest announcement is out from Catalent ( (CTLT) ).
Novo Holdings completes $16.5 billion takeover of Catalent
Novo Holdings has completed its $16.5 billion acquisition of Catalent, the contract drug manufacturer said on Wednesday, days after the companies disclosed that all regulatory conditions to close the deal were fulfilled.
Novo Holdings set to close $16.5B Catalent buy in 'coming days' after deal clears antitrust hurdles
After clearing all regulatory hurdles associated with its proposed buyout of CDMO Catalent, Novo Holdings is nearly ready to unwrap its $16.5 billion present just in time for the holidays.
Novo Completes $16.5 Billion Acquisition of Catalent
Novo Holdings A/S said Monday that it has completed its $16.5 billion all-cash acquisition of Catalent ( CTLT, Financials ). Catalent will be privately held by Danish life sciences investment business Novo Holdings and provide pharmaceutical and biotechnology services worldwide.
Novo Holdings completes purchase of Catalent
Novo Holdings said that it completed it's $16.5 billion acquisition of Catalent Inc. (NYSE:CTLT). Shortly following the completion of the deal, Novo Nordisk A/S (NVO)  will acquire from Novo Holdings Catalent’s three fill-finish sites located in Anagni,
Novo Holdings says its acquisition of Catalent will be complete 'in the coming days'
Indications are that Novo will be investing in both the plant and the community,” an Indiana University professor said.
pharmaphorum11h
Novo Holdings leads $100m round for novel painkiller biotech
The Series C – which was led by Novo Nordisk's parent company Novo Holdings – follows a $15 million second round for the ...
FierceBiotech13h
Novo Holdings leads SiteOne's $100M series C for non-opioid pain treatments
SiteOne Therapeutics is powering up with $100 million to advance its early pipeline of non-opioid therapeutics that target ...
Business Insider13h
Novo Holdings Acquires Catalent In $16.5 Bln Cash Deal
(RTTNews) - Wednesday, Novo Holdings A/S completed the acquisition of Catalent, Inc. (CTLT), a global contract development and manufacturing organization, in an all-cash transaction worth ...
STAT2d
Pharmalittle: We’re reading about Novo Holdings proceeding with Catalent deal, Sanofi threatened with sanctions, and more
Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...
Novo Holdings Completes Acquisition of Catalent
Catalent, Inc. ("Catalent"), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences investment ...
MM&M3d
Novo Holdings’ $16.5B deal for Catalent clears last regulatory hurdle
Novo Holdings is on track to acquire Catalent, a global contract development and manufacturing organization, in a $16.5 ...
Barron's on MSN2d
Novo’s New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way.
The end of Novo Nordisk’s supply problems could bring new headaches for the rest of the pharmaceutical industry, which now ...